NCT04004195View on ClinicalTrials.gov

Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 10, 2019

Primary Completion Date

February 7, 2020

Study Completion Date

June 4, 2020

Conditions

Pharmacokinetics

Interventions

DRUG

BAY2327949

A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)

Trial Locations (2)

24105

CRS Clinical-Research-Services Kiel GmbH, Kiel

81241

APEX GmbH, München